Business Description
Orchard Therapeutics PLC
NAICS : 325412
SIC : 2836
Share Class Description:
STU:OT10: ADRDescription
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.62 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.6 | |||||
| Debt-to-EBITDA | -0.72 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.22 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 87.2 | |||||
| 3-Year EBITDA Growth Rate | 12.9 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 29.4 | |||||
| 3-Year Book Growth Rate | -36.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.27 | |||||
| 9-Day RSI | 64.75 | |||||
| 14-Day RSI | 61.92 | |||||
| 6-1 Month Momentum % | 211.69 | |||||
| 12-1 Month Momentum % | 171.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | |||||
| Quick Ratio | 2.98 | |||||
| Cash Ratio | 2.54 | |||||
| Days Inventory | 269.54 | |||||
| Days Sales Outstanding | 118.81 | |||||
| Days Payable | 381.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.4 | |||||
| Shareholder Yield % | -15.76 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.17 | |||||
| Operating Margin % | -467.13 | |||||
| Net Margin % | -333.9 | |||||
| FCF Margin % | -431.59 | |||||
| ROE % | -71.08 | |||||
| ROA % | -33.01 | |||||
| ROIC % | -146.26 | |||||
| ROC (Joel Greenblatt) % | -234.22 | |||||
| ROCE % | -41.55 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.91 | |||||
| PB Ratio | 4.73 | |||||
| Price-to-Tangible-Book | 4.92 | |||||
| EV-to-EBIT | -4.37 | |||||
| EV-to-EBITDA | -4.54 | |||||
| EV-to-Revenue | 13.85 | |||||
| EV-to-Forward-Revenue | 5.34 | |||||
| EV-to-FCF | -3.2 | |||||
| Price-to-Net-Current-Asset-Value | 11.97 | |||||
| Price-to-Net-Cash | 108.57 | |||||
| Earnings Yield (Greenblatt) % | -22.88 | |||||
| FCF Yield % | -24.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orchard Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 20.406 | ||
| EPS (TTM) (€) | -3.739 | ||
| Beta | 0 | ||
| Volatility % | 126.84 | ||
| 14-Day RSI | 61.92 | ||
| 14-Day ATR (€) | 0.268421 | ||
| 20-Day SMA (€) | 14.74 | ||
| 12-1 Month Momentum % | 171.7 | ||
| 52-Week Range (€) | 4.02 - 15.5 | ||
| Shares Outstanding (Mil) | 22.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orchard Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orchard Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Orchard Therapeutics PLC Frequently Asked Questions
What is Orchard Therapeutics PLC(STU:OT10)'s stock price today?
The current price of STU:OT10 is €15.20. The 52 week high of STU:OT10 is €15.50 and 52 week low is €4.02.
When is next earnings date of Orchard Therapeutics PLC(STU:OT10)?
The next earnings date of Orchard Therapeutics PLC(STU:OT10) is 2024-05-15 Est..
Does Orchard Therapeutics PLC(STU:OT10) pay dividends? If so, how much?
Orchard Therapeutics PLC(STU:OT10) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers